Novartis AG (LON:0QLR)

London · Delayed Price · Currency is GBP · Price in CHF

126.40

-1.60 (-1.25%)

At close: Feb 20, 2026

31.41% (1Y)

Market Cap	230.69B +38.1%
Revenue (ttm)	42.11B +9.6%
Net Income	10.39B +17.1%
EPS	5.31 +21.8%
Shares Out	n/a
PE Ratio	22.20
Forward PE	18.34
Dividend	3.07 (2.43%)
Ex-Dividend Date	Mar 11, 2025

Volume	1,408,861
Average Volume	1,263,006
Open	127.17
Previous Close	128.00
Day's Range	125.32 - 127.40
52-Week Range	81.22 - 129.52
Beta	0.46
RSI	71.95
Earnings Date	Feb 4, 2026

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]

Industry Pharmaceutical Preparations

Founded 1996

Employees 75,267

Stock Exchange London Stock Exchange

Ticker Symbol 0QLR

Full Company Profile

Financial Performance

In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.

Financial numbers in USD Financial Statements